跳到正文
原文
Medical Xpress·· 3 小时前AI 评分60

ASMBS与OAC联合发布肥胖治疗可及性州级评分卡,36个州获C及以下评级

New state-by-state scorecard reveals wide gaps in access to obesity treatments

AI 导读

美国代谢和减重外科协会(ASMBS)与肥胖行动联盟(OAC)联合开发的肥胖治疗可及性评分卡对全美50个州及哥伦比亚特区进行了排名。明尼苏达州以76.4分居首获A−,南卡罗来纳、爱达荷、西弗吉尼亚、俄克拉荷马和阿肯色位列末五位得D至F。

正文
weight loss clinic
Credit: RDNE Stock project from Pexels

Where Americans live can make a profound difference in their ability to access obesity treatment, according to a new state-by-state scorecard and report that gives 20 states D or F grades and finds significant barriers to care in every state in the nation.

With states averaging a C− and only one earning an A−, the report reveals major differences in insurance coverage, treatment restrictions and utilization, and available specialists and facilities, leaving millions of Americans struggling to receive treatment even as obesity rates remain high nationwide.

Developed by the American Society for Metabolic and Bariatric Surgery (ASMBS) and the Obesity Action Coalition (OAC), the Obesity Treatment Access Scorecard ranks each of the 50 states and the District of Columbia for their residents' ability to access comprehensive obesity care, including nutrition counseling, behavioral interventions, FDA-approved medications, endoscopic therapies, metabolic and bariatric surgery, and long-term follow-up care. Researchers made assessments based on 44 metrics of access.

Minnesota emerged as the best state in the nation for access to obesity treatment with a score of 76.4 out of 100 (A−), followed by New York (71.6, B+), Massachusetts (71.5, B+), Delaware (70.6, B+) and Rhode Island (67.9, B). The five worst were South Carolina (30.9, D), Idaho (30.2, D−), West Virginia (28.9, F), Oklahoma (28.5, F) and Arkansas (25.5, F). Several big states also performed poorly or received middling grades, including Texas (39.0, D), Florida (40.6, D+), California (49.8, C−) and Pennsylvania (49.0, C−).

The results suggest a troubling overlap between high obesity prevalence and poor access to care. West Virginia and Oklahoma, both graded F, are among the states with the highest adult obesity rates and the poorest access, though the study was not designed to determine a causal link.

The CDC puts obesity prevalence at roughly 4 in 10 adults in these states, raising concerns that people in places with significant needs may face some of the biggest obstacles to obtaining care. Conversely, high obesity rates do not necessarily correspond to poor treatment access. Minnesota, ranked first in the nation for access with an A− grade, still has an adult obesity rate of about 33%.

"Coverage alone does not guarantee access or treatment. Many other barriers interfere with patients' ability to receive care, from prior authorization requirements and treatment exclusions to shortages of qualified specialists, high out-of-pocket costs and long distances to comprehensive treatment centers and physicians. All can delay or prevent people from receiving treatments that could significantly improve their health and quality of life, and it's playing out in every state in America," said John Scott, vice president of ASMBS.

Access to newer obesity medications is also becoming increasingly uncertain. According to the report, seven state Medicaid programs ended or planned to end coverage of GLP-1 medications used to treat obesity in 2026, potentially disrupting treatment for a chronic disease. Private insurers and employers are also increasingly dropping coverage, and without insurance, the cost of the drugs is prohibitively high for many patients.

Metabolic and bariatric surgery remains one of the most underutilized treatments in medicine, with a yearly utilization rate of about 1% due to restrictions on eligibility, physician referral patterns, misperceptions about safety and effectiveness, treatment bias and challenges receiving long-term care after surgery.

"Your ZIP code should not determine whether you can get proven treatments for obesity, yet the scorecard shows that where you live does make a real difference," said Joseph Nadglowski, president and CEO of the Obesity Action Coalition. "People deserve access to the full range of evidence-based treatments without unnecessary barriers, discrimination or stigma. This scorecard is meant to give policymakers, insurers, employers, health care professionals and advocates a way to identify and understand barriers and pursue state-specific solutions."

Scorecard identifies six priorities to close gaps in access

The scorecard groups its 44 measures of access into six categories: coverage and eligibility; barriers and cost; workforce and facilities; policy environment; patient context and equity; and treatment utilization.

The report identifies six priorities for improving access nationwide:

  • Expand comprehensive coverage for the full range of evidence-based obesity treatments.
  • Reduce unnecessary restrictions and administrative barriers that delay or prevent care.
  • Strengthen the health care workforce and expand access to qualified obesity specialists and accredited treatment facilities.
  • Address geographic disparities through better referral networks, telehealth and travel support.
  • Measure meaningful access, including whether patients can obtain and continue treatment, rather than simply whether a benefit is listed as covered.
  • Eliminate weight bias and discrimination in health care policies and delivery.
Key medical concepts

Obesity

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: New state-by-state scorecard reveals wide gaps in access to obesity treatments (2026, November 19) retrieved 19 November 2026 from https://medicalxpress.com/news/2026-11-state-scorecard-reveals-wide-gaps.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com